Results 211 to 220 of about 17,769,272 (338)

Correction: Limited immune perturbations in mice exposed to sustained low-dose ionizing radiation

Frontiers in Immunology
Bryan Marr, Holly Laakso, Melinda Blimkie, Andrew Cao, Seung-Hwan Lee, Seung-Hwan Lee, Seung-Hwan Lee, Abrar Ul Haq Khan, Abrar Ul Haq Khan, Abrar Ul Haq Khan   +9 more
doaj   +1 more source

The LDR BURST trial: a randomised controlled trial comparing the side effects of low-dose-rate brachytherapy against ultra-hypofractionated radiotherapy using spacer gel treatment in men with Cambridge Prognostic Groups 1-3 prostate cancer. [PDF]

BMJ Open
Hayhurst W, Uribe-Lewis S, Uribe J, Mikropoulos C, Otter S, Goh C, Mehta S, Wood K, Deering C, Higgins D, Langley S, Long M, Michael A, Langley S, Perna C.   +14 more
europepmc   +1 more source

Paclitaxel induces NM2‐dependent cellular contraction through GEF‐H1 dissociation from microtubules and RhoA/ROCK activation in cancer cells

Molecular Oncology, EarlyView.
Taxanes are widely used chemotherapeutics whose effects on cellular mechanics remain poorly understood. We show that paclitaxel induces rapid cellular contraction by promoting GEF‐H1 dissociation from microtubules and non‐muscle myosin II activation through RhoA/ROCK.
Gloria Asensio‐Juárez, Rafael Pérez‐Díaz, Hugo Ramos‐Solano, Marina Garrido‐Casado, Vanessa C. Talayero, Miguel Vicente‐Manzanares   +5 more
wiley   +1 more source

Impact of near continuous low dose rate neutron irradiation on pregnancy outcomes in mice. [PDF]

NPJ Microgravity
Steller JG, Blue RS, Ronca AE, Goodspeed A, Powell TL, Jansson T.   +5 more
europepmc   +1 more source

Bridging the gap: a genetically validated avian chorioallantoic membrane platform for investigation of spontaneous circulating tumor cells

Molecular Oncology, EarlyView.
We established the avian chorioallantoic membrane (CAM) assay as a scalable in vivo model for studying circulating tumor cells (CTCs). Human gastrointestinal tumors spontaneously released genetically validated CTCs that were detected across multiple platforms, demonstrating that the CAM model provides an accessible tool for investigating early cancer ...
Dennis Roth, Rui P. L. Neves, Julia Geheb, Christian Ballmeyer, Nathalie Gaßmann, Kiki C. Andree, Monica Sudarsanam, Christiane Driemel, Celine Örencik, Andrè Franken, Eslam Elmaghraby, Sven H. Loosen, Roderburg Christoph, Sebastian Schoelch, Hans Neubauer, Wolfram T. Knoefel, Nikolas H. Stoecklein, Georg Fluegen   +17 more
wiley   +1 more source

Androgen Deprivation Benefits in Low-Dose-Rate Brachytherapy With Hydrogel Spacer. [PDF]

Cureus
Kikuchi K, Ishii S, Ieko Y, Segawa T, Nakamura R, Ariga H.   +5 more
europepmc   +1 more source

SPHINX31 acts as a SRPK1 inhibitor targeting the ATR/DNA‐PKcs/CHK1 replicative checkpoint to inhibit cell growth in non‐small cell lung cancer

Molecular Oncology, EarlyView.
The kinase SRPK1 directly interacts with the protein TOPBP1 and regulates the pre‐mRNA splicing of WIZ thereby contributing to the activation of the ATR/CHK1 replicative checkpoint in response to replicative stress. This allows cancer cells' genomic stability and survival.
Amani Shreim, Aurelie Genoux, Nadiia Zubchuk, Haoyang Zheng, Perla Salameh, Theo Ziegelmeyer, Fabien Dalonneau, Margot Rouchette, Christiane Oddou, Simona Miron, Helene Polveche, Adiilah Mamode Cassim, Carmen Garrido, Eleni Nikolakaki, Didier Auboeuf, Tao Jia, Sophie Zinn‐Justin, Beatrice Eymin   +17 more
wiley   +1 more source

Predicting Urinary Function Outcomes Following Low-dose-rate Brachytherapy for Prostate Cancer. [PDF]

Eur Urol Open Sci
Rüedi G, Pratsinis M, Schmid HP, Güsewell S, Putora PM, Plasswilm L, Schwab C, Burkhardt O, Thoeni A, Hochreiter W, Prikler L, Suter S, Stucki P, Müntener M, Blick N, Schiefer H, Müllhaupt G, Engeler DS.   +17 more
europepmc   +1 more source

Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation

Molecular Oncology, EarlyView.
How mutant p53R273H drives AKT signaling is unclear. We show that p53R273H, but not wild‐type, directly binds PDPK1 via a mutation‐dependent conformational change. This interaction disrupts inhibitory PDPK1 homodimerization and enhances AKT phosphorylation.
Mei Chee Lim, Alvin Kunyao Guo, Yoko Itahana, Srinivasaraghavan Kannan, Valerie Goh, Mingmin Ong, Terina Yan Wen Tay, Weiying Ye, Sabhashina Radha Krishnan, Jun Nishiyama, Chandra S Verma, Koji Itahana   +11 more
wiley   +1 more source

Dosiomic predictors of biochemical failure in patients with localized prostate cancer treated with Iodine-125 low-dose-rate brachytherapy. [PDF]

Radiat Oncol
Nakano M, Kaji S, Kawakami S, Tsumura H, Imae T, Tanaka Y, Fujii K, Kainuma T, Yamazaki R, Uchida A, Kaneko H, Fujino M, Hata C, Murakami Y, Hashimoto M, Ishiyama H.   +15 more
europepmc   +1 more source